Rajat Thawani, M.D.

Rajat Thawani, M.D., is an Assistant Professor of Medicine and Medical Oncologist at Oregon Health & Science University. His research focuses on thoracic oncology, specifically targeted therapies and immunotherapies for non-small cell lung cancer (NSCLC), including EGFR-mutated disease and BRAF V600E-mutated metastatic NSCLC. He has published extensively on tumor-agnostic therapy approvals, MTAP deficiency in thoracic malignancies, and novel agents such as tarlatamab rechallenge in small cell lung cancer. His recent work includes a multicentre retrospective cohort study in The Lancet Oncology evaluating first-line immunotherapy versus BRAF/MEK inhibitors, alongside investigations into neoadjuvant chemoimmunotherapy for unresectable Stage III NSCLC.